However, only 3 patients who transitioned to ruxolitinib had a complete response (CR) compared with 11 patients in the initial ruxolitinib arm, and 43.5% (n = 30) of patients who crossed over had a partial response (PR) compared with 43% (n = 71) in the original treatment arm.Īmong nonresponders who crossed over and were treated with ruxolitinib, 5 (7.2%) died during the course of treatment, 6 (8.7%) had a mixed response, and 4 (5.8%) experienced disease progression. According to Franco Locatelli, MD, who presented the data at the EBMT meeting, the ORR indicates that patients who cross over to ruxolitinib can still achieve a high response. Results of the follow-up analysis were presented at the European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting and showed that at 24 weeks after crossover the overall response rate (ORR) of patients who transitioned to ruxolitinib (n = 69) was 47.8% (95% CI, 35.6%-60.2%), which was similar to the initial ORR of 49.7% (95% CI, 41.8%-57.6%) for patients who started on ruxolitinib (n = 165). Patients with chronic graft-versus-host disease (GVHD) who crossed over to ruxolitinib (Jakafi) from the best available therapy (BAT) arm of the REACH3 study (NCT03112603) experienced response rates with ruxolitinib that were similar to those of patients who started the trial on ruxolitinib.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |